Kura Oncology (KURA) Other Non-Current Liabilities (2014 - 2026)
Kura Oncology (KURA) reported Other Non-Current Liabilities of $3.4 million for Q1 2026, up 60.68% year-over-year from $2.1 million in Q1 2025, and up 8.59% on a QoQ basis from $3.2 million in Q4 2025.
Kura Oncology (KURA) has 13 years of Other Non-Current Liabilities data on file, last reported at $3.4 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 60.68% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 60.68% YoY) and the FY2025 annual result came in at $3.2 million, up 76.32% from the prior year.
- Other Non-Current Liabilities grew to $3.4 million in Q1 2026 per KURA's latest filing, from $3.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.4 million in Q1 2026 and bottomed at $265000.0 in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $951000.0 (2024), against an average of $1.4 million.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities fell 29.33%; it then surged 170.94% in 2024.
- Tracing KURA's Other Non-Current Liabilities over 5 years: stood at $265000.0 in 2022, then jumped by 166.04% to $705000.0 in 2023, then jumped by 154.61% to $1.8 million in 2024, then surged by 76.32% to $3.2 million in 2025, then gained by 8.59% to $3.4 million in 2026.
- Per Business Quant, the three latest KURA Other Non-Current Liabilities figures stand at $3.4 million (Q1 2026), $3.2 million (Q4 2025), and $3.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.44 Mn |
| Dec 31, 2025 | 3.17 Mn |
| Sep 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 2.14 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 951,000.00 |
| Dec 31, 2023 | 705,000.00 |
| Sep 30, 2023 | 567,000.00 |
| Jun 30, 2023 | 461,000.00 |
| Mar 31, 2023 | 351,000.00 |
| Dec 31, 2022 | 265,000.00 |
| Sep 30, 2022 | 542,000.00 |
| Jun 30, 2022 | 459,000.00 |
| Mar 31, 2022 | 496,000.00 |
| Dec 31, 2021 | 375,000.00 |
| Sep 30, 2021 | 356,000.00 |
| Jun 30, 2021 | 295,000.00 |
| Mar 31, 2021 | 441,000.00 |
| Dec 31, 2020 | 395,000.00 |
| Sep 30, 2020 | 344,000.00 |
| Jun 30, 2020 | 306,000.00 |
| Mar 31, 2020 | 2.21 Mn |
| Dec 31, 2019 | 377,000.00 |
| Sep 30, 2019 | 406,000.00 |
| Jun 30, 2019 | 372,000.00 |
| Mar 31, 2019 | 385,000.00 |
| Dec 31, 2018 | 279,000.00 |
| Sep 30, 2018 | 556,000.00 |
| Jun 30, 2018 | 500,000.00 |
| Mar 31, 2018 | 446,000.00 |
| Dec 31, 2017 | 388,000.00 |
| Sep 30, 2017 | 336,000.00 |
| Jun 30, 2017 | 279,000.00 |
| Mar 31, 2017 | 223,000.00 |
| Dec 31, 2016 | 170,000.00 |
| Sep 30, 2016 | 58,000.00 |
| Jun 30, 2016 | 27,000.00 |
| Dec 31, 2015 | 101,000.00 |
| Sep 30, 2015 | 332,000.00 |
| Jun 30, 2015 | 503,000.00 |
| Mar 31, 2015 | 391,000.00 |
| Dec 31, 2014 | 1.30 Mn |